Brad Deutser's Deutser Clarity Institute opens on May 1. Courtesy of DCI

Brad Deutser is taking his approach to business consulting and creative thinking to a whole new level with the Deutser Clarity Institute. The idea accelerator, think tank, and learning lab opens next month in Uptown.

"The Deutser Clarity Institute has captured the imagination of leaders across the country," says Deutser in a release. "Even with the available science on environmental design and leadership learning, we took a chance and pushed creativity and innovation to the farthest reaches to develop a fundamentally different space, way of learning and learning curriculum. We are also producing game changing research which will influence how leaders drive engagement." (Deutser serves on the board of InnovationMap.)

It's the first location for the Houston-based consultancy, which has a diverse staff made up of academicians, business leaders, professional athletes, and more. Deutser — who published his business strategy book, Leading Clarity, last year — has a goal to translate scientific studies and research into immersive education for business leaders. The institute's website describes it as "Wonkaland for business" and is supposed to surround its visitors with an imaginative space for clients' creative exploration.

Here are some design elements you can expect at DCI, according to the release:

  • A 6-by-6-foot glass "Clarity Performance Index"
  • A 10-by-10-foot energy obstruction grid
  • 15 magic spinning cubes (games on two sides, whiteboard on one side and clarity exercise on one side of each cube)
  • A "higher thinking" leadership game/journey on the ceiling
  • A mirrored reflection room with exercises on each mirror and window pane
  • The brain labyrinth
  • A positivity beam
  • A "leadership weave" which is a live research project on leadership competencies by industry.
  • Tactile and engaging tools, like: magnets, stickers, colorful markers, multi-sized sticky notes and more.

Along with its grand opening, DCI is releasing its findings from a study on employee engagement. According to the release, the study analyzed over 13,500 employees in 13 areas that correlate to performance of organizations. Three of the 13 areas — vision + values, leadership, and team capability — have the biggest impact on employee retention and engagement.

InnovationMap is co-hosting the grand opening of the space.

Creative space

Courtesy of DCI

The institute was designed with creativity in mind.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.